Patent application number | Description | Published |
20090305432 | Polypeptide Molecular Switch - A polypeptide can conduct electricity in a closed circuit. Conformational changes in the polypeptide due to posttranslational modifications or ligand binding can effect the conductive properties of the polypeptide which can be measured. In such a closed circuit, a polypeptide having at least one residue capable of reversible modification can be used as a molecular switch. Circuits comprising such molecular switches can be used, for example, in methods for assessing the modification state of a polypeptide, determining the activity of an enzyme of interest, identifying compounds that affect the activity of an enzyme of interest, storing data, detecting the presence of a compound and identifying inhibitors of protein-protein interactions. | 12-10-2009 |
20100068690 | TISSUE PRESERVATION AND FIXATION METHOD - This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that is effective to fix the phosphoproteins, and that has a sufficient water content to be soluble for a stabilizer and/or a permeability enhancing agent); (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; and (3) a permeability enhancing agent (e.g. PEG). Methods are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. the following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample. | 03-18-2010 |
20130345075 | Tissue Preservation and Fixation Method - This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that stabilizes the proteins in the sample and that has a sufficient water content for a stabilizer and/or a permeability enhancing agent to be soluble therein; (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; (3) a permeability enhancing agent; and (4) lactic acid. Methods and kits are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample. | 12-26-2013 |
Patent application number | Description | Published |
20100107719 | Necking die with shortened land and method of die necking - The exemplary embodiments provide a die set comprising a knockout punch and a necking die for necking-in a metal container preform. In an axial direction from front to back of the die, the die has an inwardly tapering in-feed surface, a forming radius, a generally cylindrical land having a die bore diameter, a discharge surface and a relief surface having a diameter larger than the die bore diameter. The land has an axial length of less than 0.1 inch. It is believed that such a length limits the number of metal contacts with the land (rebounds between the knockout punch and the land) to one or two as a metal container preform is necked in the die in conjunction with a knockout punch having a punch diameter that provides a gap between the knockout punch and the land. While the gap may be larger than the topwall thickness of the metal of the preform within the gap, it may alternatively be the same as, or smaller than, the thickness (by up to 10%), to effect re-resizing of the container wall. The exemplary embodiments also provide a method of necking a container preform using such a die. | 05-06-2010 |
20100159266 | Clad can body stock - The invention relates to can body stock having opposed surfaces. The can body stock has a core layer, a cladding layer at a first surface (intended to form an exterior surface of an eventual container body), and optionally a cladding layer at a second surface (intended to form an interior surface of an eventual container body). The cladding layer at the first surface is made of alloy AA3104 or AA3004 (or a modified version of AA3004 or AA3104 containing more iron and optionally more silicon), and the core layer is an aluminum alloy having yield strength less than that of the aluminum alloy of the cladding layer at the first surface. The can body stock may be used to produce a container body by a method involving drawing and ironing, as well as die necking to reduce the diameter of the open end of the container body. | 06-24-2010 |
20100159275 | Clad can stock - Exemplary embodiments of the invention relate to a sheet article having opposed first and second surfaces, and having a core layer, a cladding layer at the first surface of the sheet article, and optionally a cladding layer at the second surface of the sheet article. The cladding layer at the first surface is made of an aluminum alloy selected from alloys AA3104, AA3004 and modified versions of alloys AA3104 and AA3004 additionally containing 1.0 to 2.0 wt % Fe and optionally up to 1 wt % Si. The core layer is an aluminum alloy having a yield strength and/or ductility greater than the yield strength and/or ductility of the alloy of the cladding layer at the first surface. The sheet article may be used as can body stock, can end stock and tab stock. | 06-24-2010 |
Patent application number | Description | Published |
20090087479 | Orally bioavailable lipid-based constructs - The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetucic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents. | 04-02-2009 |
20100080773 | Orally Bioavailable Lipid-Based Constructs - The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetuic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents. | 04-01-2010 |
20100129428 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL - The instant invention is drawn to a hepatocyte targeted composition comprising interferon associated with a lipid construct comprising amphipathic lipid molecules and receptor binding molecule. The composition can comprise a mixture of free interferon and interferon associated with the complex. The composition can be modified to protect interferon and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading interferon into the composition and recycling various components of the composition and methods of treating individuals infected with the hepatitis C and other hepatitis viruses. | 05-27-2010 |
20100209492 | Targeted Liposomal Drug Delivery System - A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use. | 08-19-2010 |
20100247625 | Orally Bioavailable Lipid-Based Constructs - The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof. | 09-30-2010 |
20100310599 | Orally Bioavailable Lipid-Based Constructs - The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof. | 12-09-2010 |
20110135725 | Lipid Construct for Delivery of Insulin to a Mammal - The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes. | 06-09-2011 |
20110135727 | Hepatocyte Delivery Vehicle for Delivery of a Combination of Recombinant Human Regular Insulin and Recombinant Human Insulin Isophane to a Mammal - The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Recombinant human insulin isophane and Recombinant human regular insulin insulin are present within the complex in at least one form wherein the recombinant human insulin isophane and Recombinant human regular insulin insulin have regions of positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes. | 06-09-2011 |
20120035105 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments - The present invention includes a pharmaceutical composition comprising HDV insulin or oral HDV insulin, and one or more additional therapeutic agents useful for the treatment of diabetes and diabetes related ailments. The present invention also includes a method of making the pharmaceutical inventions of the application. The present invention further includes methods of treating diabetes and/or diabetes related ailments comprising administering a pharmaceutical composition of the invention to a patient in need thereof. The present invention also includes methods of treating diabetes related ailments comprising administering a pharmaceutical formulation of HDV insulin or a pharmaceutical formulation of oral HDV insulin. | 02-09-2012 |
20130183270 | Orally Bioavailable Lipid-Based Constructs - The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetuic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents. | 07-18-2013 |
20130267462 | Lipid Construct for Delivery of Insulin to a Mammal - The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes. | 10-10-2013 |
20140243430 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS - The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof. | 08-28-2014 |
20150031608 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL - The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes. | 01-29-2015 |
20150125518 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS - The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents. | 05-07-2015 |